Seagen

E854988

Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.

Try in SPARQL Jump to: Statements Referenced by

Statements (47)

Predicate Object
instanceOf biotechnology company
public company
acquiredBy Pfizer NERFINISHED
acquisitionAnnounced 2022
acquisitionValueUSD 43000000000
AdcetrisIndication Hodgkin lymphoma NERFINISHED
systemic anaplastic large cell lymphoma
collaboratesWith Astellas Pharma NERFINISHED
Genmab NERFINISHED
Merck & Co. NERFINISHED
Takeda Pharmaceutical Company NERFINISHED
coreModality cytotoxic payloads
linker technologies NERFINISHED
monoclonal antibodies
country United States of America
surface form: United States
developed Adcetris NERFINISHED
enfortumab vedotin NERFINISHED
focusesOn cancer treatment
targeted cancer therapies
formerName Seattle Genetics NERFINISHED
foundedBy Clay Siegall NERFINISHED
H. Perry Fell NERFINISHED
hasEmployeeType clinical researchers
scientists
hasProduct Adcetris NERFINISHED
Padcev NERFINISHED
Tukysa NERFINISHED
hasTechnology antibody-drug conjugate platform
hasTherapy brentuximab vedotin NERFINISHED
enfortumab vedotin NERFINISHED
tisotumab vedotin NERFINISHED
tucatinib NERFINISHED
headquartersLocation Bothell, Washington NERFINISHED
inception 1997
industry biotechnology
pharmaceuticals
locatedIn Washington
surface form: Washington (state)
PadcevIndication urothelial carcinoma
regulatoryRegion FDA-approved products
researchArea hematologic malignancies
solid tumors
specializesIn antibody-drug conjugates
oncology therapeutics
tickerSymbol SGEN NERFINISHED
tisotumabVedotinIndication recurrent or metastatic cervical cancer
tradedOn NASDAQ NERFINISHED
TukysaIndication HER2-positive breast cancer

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Genmab collaboratesWith Seagen